Discussion Paper

Can Preferentially Prescribing Angiotensin II Receptor Blockers (ARBs) over Angiotensin-Converting Enzyme Inhibitors (ACEIs) Decrease Dementia Risk and Improve Brain Health Equity?

Can Preferentially Prescribing Angiotensin II Receptor Blockers (ARBs) over Angiotensin-Converting Enzyme Inhibitors (ACEIs) Decrease Dementia Risk and Improve Brain Health Equity?

  Currently, there are no effective disease-modifying treatments for Alzheimer’s disease and related dementias (ADRD) (National Institute on Aging, 2021). In this context, considerable attention has been given to prevention of ADRD. The 2020 report of the Lancet...

Join Our Community

Sign up for NAM email updates